The cannabinoid receptor 1 (CB1) antagonist, rimonabant has demonstrated efficacy in treating obesity albeit with the risk of significant neuropsychiatric side effects. The gene discussed is CNR1; the disease is obesity due to melanocortin 4 receptor deficiency.